Eftilagimod alfa
- Generic Name
- Eftilagimod alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1800476-36-1
- Unique Ingredient Identifier
- SJ82PK3HWA
- Background
Eftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Eftilagimod Alfa (Efti) in Combination with Pembrolizumab and Chemotherapy Versus Placebo in Combination with Pembrolizumab and Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Immutep S.A.S.
- Target Recruit Count
- 756
- Registration Number
- NCT06726265
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath